Mimedx (MDXG) Share-based Compensation (2011 - 2026)
Mimedx (MDXG) posted Share-based Compensation of $127000.0 for Q2 2026, down 93.32% sequentially from $1.9 million in Q1 2026, and down 97.33% YoY from $4.8 million in Q2 2025.
Mimedx (MDXG) Share-based Compensation (2011 - 2026) Analysis & Trends
Mimedx has reported Share-based Compensation for 16 years, with the latest figure at $127000.0 in Q2 2026.
- Quarterly Share-based Compensation fell 97.33% year-over-year to $127000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.4 million (down 46.28% YoY) and the FY2025 annual result came in at $16.4 million, down 3.17% from the prior year.
- Share-based Compensation slipped to $127000.0 in Q2 2026 per MDXG's latest filing, from $1.9 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.9 million in Q3 2025 and troughed at $127000.0 in Q2 2026.
- A 5-year average of $3.5 million and a median of $4.1 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation surged 727.55% in 2023, then slumped 97.33% in 2026.
- Over 5 years, Share-based Compensation stood at $530000.0 in 2022, then soared by 727.55% to $4.4 million in 2023, then gained by 7.0% to $4.7 million in 2024, then plunged by 47.52% to $2.5 million in 2025, then sank by 94.84% to $127000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $127000.0, $1.9 million, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 127,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 127,000.00 |
| Jun 30, 2026 | 127,000.00 |
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 2.46 Mn |
| Dec 31, 2025 | 2.46 Mn |
| Sep 30, 2025 | 4.92 Mn |
| Sep 30, 2025 | 4.92 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.26 Mn |
| Mar 31, 2025 | 4.26 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 3.81 Mn |
| Sep 30, 2024 | 3.81 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Mar 31, 2024 | 4.34 Mn |